 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: DAB389 IL2 | denileukin diftitox-cxdl | LY 335348 | Lymphir® | Ontak®
                                 denileukin diftitox is an approved drug (FDA (1999)) Compound class: 
                                                            Peptide
                                 
                                    
                                        Comment: Denileukin diftitox is an anti-cancer immunotherapy drug that was designed to target and eradicate malignant (IL-2 receptor-expressing) T cells. It is a recombinant protein containing peptide sequences of both interleukin-2 and diphtheria toxin [1,5]. It simultaneously directly kills IL-2R expressing tumour cells and promotes depletion of host Treg cells which enhances the immune response
                                    
                                 | 
| Classification  | |
| Compound class | Peptide | 
| Approved drug? | Yes. US FDA (1999) | 
| International Nonproprietary Names  | |
| INN number | INN | 
| 7680 | denileukin diftitox | 
| Synonyms  | 
| DAB389 IL2 | denileukin diftitox-cxdl | LY 335348 | Lymphir® | Ontak® | 
| Database Links  | |
| Specialist databases | |
| IMGT/mAb-DB | 704 | 
| Other databases | |
| CAS Registry No. | 173146-27-5 (source: SciFinder) | 
| ChEMBL Ligand | CHEMBL1201550 | 
| DrugBank Ligand | DB00004 | 
| GtoPdb PubChem SID | 178103623 | 
| Search PubMed clinical trials | denileukin diftitox | 
| Search PubMed titles | denileukin diftitox | 
| Search PubMed titles/abstracts | denileukin diftitox | 
| Wikipedia | Denileukin_diftitox |